| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 11th November 2020 | Carl Goldfischer | 5,000 | Open or private purchase | $12.07 | $60,350.00 |
| 16th March 2020 | Carl Goldfischer | 690,232 | Conversion of derivative | $0.00 | |
| 16th March 2020 | Carl Goldfischer | 13,148 | Conversion of derivative | $0.00 | |
| 10th October 2019 | Sujal Shah | 5,000 | Open or private purchase | $4.30 | $21,500.00 |
| 23rd September 2019 | Sujal Shah | 3,100 | Open or private purchase | $5.55 | $17,205.00 |
| 20th September 2019 | Sujal Shah | 1,900 | Open or private purchase | $5.50 | $10,450.00 |
| 7th February 2019 | Carl Goldfischer | 2,335 | Exercise of derivative | $5.00 | $11,675.00 |
| 7th February 2019 | Carl Goldfischer | 9,340 | Exercise of derivative | $5.50 | $51,370.00 |
| 7th February 2019 | Carl Goldfischer | 11,675 | Open or private sale | $9.02 | $105,328.35 |
Cyma Bay Therapeutics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company. Its products include MBX-8025 and Arhalofenate. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
Ticker: CBAY
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1042074
Employees: 43
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Restructuring Charges of $188 Th for the period Apr 2020 to Jun 2020 in the context of all up
Restructuring Charges of $117 Th for the period Jan 2020 to Jun 2020 in the context of all up
Restructuring Charges of $48 M for the period Jan 2020 to Jun 2020 in the context of Prepaid research and development costs
Fundamentals
Cash at Carrying Value: $96 M (286%)
Assets, Current: $174 M (-14%)
Property, Plant and Equipment, Net: $2 M (-13%)
Other Assets, Noncurrent: $160 Th (0%)
Assets: $177 M (-14%)
Accounts Payable, Current: $476 Th (-80%)
Liabilities, Current: $9 M (-46%)
Liabilities: $11 M (-43%)
Common Stock, Value, Issued: $7 Th (0%)
Common Stock, Shares, Issued: $69 M (0%)
Retained Earnings (Accumulated Deficit): $650 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $186 Th (132%)
Stockholders' Equity (Parent): $166 M (0%)
Liabilities and Equity: $177 M (-14%)
Research and Development: $8 M (-54%)
General and Administrative Expenses: $3 M (-56%)
Restructuring Charges: $188 Th (60%)
Operating Income/Loss: $11 M (-55%)
Other Income, net: $426 Th (-66%)
EPS (basic): $0.16 (0%)
EPS (diluted): $0.16 (0%)
News
CymaBay Therapeutics (CBAY) Presents At AASLD 2020 Conference- Slideshow
17th November 2020
Stocks To Watch: Spotlight On Nvidia, Walmart, JD.com And Nio
14th November 2020
CymaBay Therapeutics to Present at Upcoming Investor Conferences
11th November 2020
CymaBay Is Clawing Back, Now We Just Need Pipeline Conversion
8th November 2020